PAOG CEO Interview: Cannabis Pharma News; Acquir
Post# of 107586
(Total Views: 211)
Posted On: 08/07/2020 1:07:42 PM
PAOG CEO Interview: Cannabis Pharma News; Acquired Revenue; Updated Financials; Why PPS Is Undervalued And Timing Of Correction
August 07 2020 - 12:33PM
InvestorsHub NewsWire
Share On Facebook
Sandusky, OH -- August 7, 2020 -- InvestorsHub NewsWire -- PAO Group, Inc. (USOTC: PAOG) today announced an interview of CEO James C. DiPrima on MoneyTV with Donald Baillargeon. The interview is available on the MoneyTV website discussing new cannabis pharmaceutical developments, a recently acquired revenue stream, upcoming financial reports bringing the company current with OTC Markets and discussing why the current price per share (PPS) of PAOG is undervalued and what event is anticipated to correct the valuation . Mr. DiPrima also appeared on MoneyTV last week following PAOG’s acquisition of two medical cannabis companies.
Interview Highlights:
Mr. DiPrima discusses PAOG’s partnership with a Contract Research Organization (CRO) and a formal agreement in the works to advance an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for RespRx (one of the two acquisitions executed by PAOG last week) as a COPD treatment.
(0)
(0)